Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer

This study will evaluate the safety and tolerability of a personalized live, attenuated, double-deleted Listeria monocytogenes (pLADD) treatment in adults with metastatic colorectal cancer.

Stanford is currently not accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • biological: pLADD

Eligibility


Inclusion Criteria:

   - metastatic colorectal cancer (mCRC) that is microsatellite stable (MSS)

   - able to provide adequate tumor tissue from at least 1 accessible tumor site

   - completed or have developed intolerance to a course of oxaliplatin- or
   irinotecan-based frontline therapy at Screening

   - on maintenance standard-of-care chemotherapies or on treatment holiday

   - Eastern Cooperative Oncology Group (ECOG) 0 or 1

   - adequate organ function

   - progression of disease at the time of Enrollment

Exclusion Criteria:

   - BRAF V600E mutation

   - known allergy to both penicillin and sulfa drugs

   - implanted devices that cannot be easily removed

   - immunodeficiency, immune compromised state or receiving immunosuppressive therapy

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting

Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation,  mobile application development, and pharmaceutical trials.  

Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.